Drug intelligence / Profile preview

escitalopram + risperidone

Development stage
Phase 4
Lead developer
Lundbeck
Modality
Small Molecules
Administration
Oral, Intramuscular
01

Overview

Escitalopram + risperidone is a combination of two pharmaceutical drugs used primarily in psychiatric practice. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain by inhibiting its reuptake, thereby improving mood and anxiety symptoms. Risperidone is an atypical antipsychotic that acts as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, reducing psychotic symptoms such as delusions and hallucinations. The combination has been studied for use in treating positive and negative symptoms of schizophrenia, especially when depressive or cognitive symptoms are present. Co-administration may enhance dopaminergic and serotonergic neurotransmission more effectively than either drug alone[2]. However, this combination carries risks including increased potential for QT prolongation (irregular heart rhythm), additive central nervous system depression, impairment of judgment/psychomotor skills, and pharmacokinetic interactions due to CYP2D6 inhibition by escitalopram leading to higher risperidone levels[1][3][4].

02

Targets

DRD2 (Dopamine D2 Receptor)HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on escitalopram + risperidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on escitalopram + risperidone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call